ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PSMA/CD3 Protease-activated T-cell Engager JANX007

Its studies are mostly in Prostatic Neoplasms, Castration-Resistant · Prostatic Neoplasms, led by Janux Therapeutics.

Furthest: phase 1, since Aug 25, 20222 company-led studies, 2 open or runningNext primary completion: Jul 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Janux Therapeutics22 open or runningphase 1since Aug 25, 2022Aug 25, 2022Jul 2027phase 1 · NCT05519449

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 25, 2022First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT05519449 · 272 planned · United States, Australia, Spain
  2. Sep 4, 2026Phase 1 study in Prostatic NeoplasmsNCT07813637 · 110 planned · United States

Ahead

  1. Jul 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT05519449
  2. Jul 2029Primary completion: phase 1 study in Prostatic NeoplasmsNCT07813637

TargetBeta

FOLH1 →read by rule
“A protease-activated, masked T-cell engager (TCE) composed of a prostate-specific membrane antigen (PSMA)-binding domain and a CD3-binding domain ”NCIt, by rule

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
piflufolastatruleLantheusphase 45
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07813637Prostatic Neoplasms · United States1RecruitingJul 2029110
NCT05519449Prostatic Neoplasms · United States, Australia, Spain1RecruitingJul 2027272

How it is read

Names in the registry

  • “JANX007”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.